Drug Database
IN
interferon (Avonex PEN / BG9015 / Avonex)
✓ ApprovedMerck & Co. · IFNB1 · Recombinant Proteins
What is interferon?
interferon is a recombinant proteins developed by Merck & Co.. It is approved for therapeutic indications via injectable (others) or intramuscular (im) injection.
Drug Profile
| Brand Names | Avonex PEN, BG9015, Avonex |
| Company | Merck & Co. |
| Drug Class | Recombinant Proteins |
| Molecular Target | IFNB1 |
| Route | Injectable (Others), Intramuscular (IM) Injection |
| Status | Approved |
Sources: ClinicalTrials.gov, Merck & Co.
Mechanism of Action
Molecular Targets
interferon acts on 1 molecular target:
| IFNB1 | interferon beta 1 (IFN-beta, IFNB) |
Want deeper analysis?Noah AI can explain complex mechanisms and compare to similar drugs.
Therapeutic Indications
interferon is developed for 12 unique indications across 5 therapeutic areas.
| Therapeutic Area | Condition | Phase |
|---|---|---|
| Nervous system disorders | Relapsing-remitting multiple sclerosis | ✓ Approved |
| Nervous system disorders | Secondary progressive multiple sclerosis | Phase III |
| Gastrointestinal disorders | Colitis ulcerative | Phase II |
| Musculoskeletal and connective tissue disorders | Rheumatoid arthritis | Phase II |
| Nervous system disorders | Chronic inflammatory demyelinating polyradiculoneuropathy | Phase II |
+7 more indications available with a free account
Sign up free to view all indications →Related Research Articles
Unable to load articles right now.